fonazine: has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions; minor descriptor (75-84); on-line & Index Medicus search PHENOTHIAZINES (75-84); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3089 |
| CHEMBL ID | 346977 |
| CHEBI ID | 135616 |
| SCHEMBL ID | 79333 |
| MeSH ID | M0262676 |
| Synonym |
|---|
| 10h-phenothiazine-2-sulfonamide, 10-[2-(dimethylamino)propyl]-n,n-dimethyl- |
| phenothiazine-2-sulfonamide, 10-(2-(dimethylamino)propyl)-n,n-dimethyl- |
| fonazine |
| 7456-24-8 |
| 10-[2-(dimethylamino)propyl]-n,n-dimethyl-10h-phenothiazine-2-sulfonamide |
| brn 0941549 |
| einecs 231-229-6 |
| dimethodin |
| bayer 1483 |
| il 6302 |
| 10-(2-(dimethylamino)propyl)-n,n-dimethylphenothiazine-2-sulfonamide |
| n,n-dimethyl-10-(2-dimethylaminopropyl)-2-phenothiazinylsulfonamid |
| dimetotiazine |
| dimetotiazina [inn-spanish] |
| dimetotiazine [inn:ban] |
| dimethylsulfamido-3-(dimethylamino-2-propyl)-10-phenothiazine |
| dimethothiazine |
| dimetiotazine |
| 3-dimethylsulfonamido 10-(2-dimethylaminopropyl)phenothiazine |
| r.p. 8599 |
| dimetotiazinum [inn-latin] |
| migristene |
| CHEBI:135616 |
| dimetotiazine (inn) |
| D07854 |
| migristene (tn) |
| 8599 r.p. |
| il-6302 |
| CHEMBL346977 |
| 10-[2-(dimethylamino)propyl]-n,n-dimethylphenothiazine-2-sulfonamide |
| dtxcid803076 |
| dtxsid6023076 , |
| cas-7456-24-8 |
| tox21_113201 |
| NCGC00249414-01 |
| unii-1fta475zdb |
| 1fta475zdb , |
| dimetotiazina |
| dimetotiazinum |
| fonazine [mi] |
| dimetotiazine [inn] |
| dimetotiazine [who-dd] |
| SCHEMBL79333 |
| rp-8599 |
| migristene (salt/mix) |
| promaquid (salt/mix) |
| dimethiotazine |
| 10-[2-(dimethylamino)propyl]-n,n-dimethyl-10h-phenothiazine-2-sulfonamide # |
| DB08967 |
| dimetotiazin |
| Q27097974 |
| dimethiotazine; dimethothiazine; fonazine |
| EN300-19767844 |
| CS-0017485 |
| HY-A0157 |
| AKOS040751843 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The recovery of these drugs and their sulphoxides in laboratory-made mixture and dosage forms has been reported." | ( Determination of isothipendyl or dimethothiazine with their sulphoxides using third- and fourth-derivatives spectroscopy on a diode-array spectrophotometer. Abdel-Hay, MH; Barary, MH; Elsayed, MA; Hassan, EM, ) | 0.13 |
| " The compound exhibiting the greatest separation between the dosage that reduced rigidity and that which caused sedation was (Z)-2-propionyl-9-[3-(dimethylamino)propylidene]thioxanthene." | ( Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat. Ashton, MJ; Chapman, RF; Loveless, AH, 1980) | 0.26 |
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 23.9145 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 33.4915 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 13.3332 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 10.5909 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 14.2300 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 3.7578 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 31.6228 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID49904 | Reduction of the integrated electromyographic response by 50% in cat after peroral administration | 1980 | Journal of medicinal chemistry, Jun, Volume: 23, Issue:6 | Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat. |
| AID49902 | Reduction of the integrated electromyographic response by 50% in cat after intravenous administration | 1980 | Journal of medicinal chemistry, Jun, Volume: 23, Issue:6 | Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat. |
| AID135601 | Reduction of locomotor activity count to 50% of the control in mouse after oral administration | 1980 | Journal of medicinal chemistry, Jun, Volume: 23, Issue:6 | Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat. |
| AID229838 | Ratio of motor activity and activity A | 1980 | Journal of medicinal chemistry, Jun, Volume: 23, Issue:6 | Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.40) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||